Page 17 - White Paper on Experimental Vaccines for Covid-19*

5. Unknown Complications.
There are entire populations for whom we don’t know the data. For example, we have no
knowledge of the immune response in vaccinated individuals who later contract the
disease, and we also do not know the effects on disease course in vaccinated individuals
with waning immunity. We do not know the effects on the elderly. We do not know the
effect on the pregnant or soon to be pregnant. There is no actual data at all for an enormous
percentage of the population, probably more than half.

Just by the mere fact that these trials were launched within the past six months, we cannot
know of any long-term effects or interactions with other viruses such as influenza or the
seasonal cold, especially considering that two of the vaccines nearest to public distribution
take an entirely novel approach with mRNA.

The mechanism of action of the experimental mRNA vaccines includes a possible auto-
immune rejection of the placenta. In layman’s terms, the vaccine may permanently
interfere with a woman’s ability to maintain a pregnancy. The vaccine companies
themselves acknowledge the possibility of ill effects on a pregnancy on the vaccine bottle,
which says the following: “it is unknown whether COVID-19 mRNA VaccineBNT162b2
has an impact on fertility. And women of childbearing age are advised to avoid pregnancy
30
for at least two months after their second dose.”

6. Pharmaceuticals are Immune from All Liability.
The same companies (and executives) that profit from this vaccine are immune from all
liability. In 1986, Congress passed the National Childhood Vaccine Injury Act (NCVIA). It
provides immunity from liability to all vaccine manufacturing companies. With COVID-19
experimental vaccine, AstraZeneca goes even further in acknowledging that this is an
emergency situation and requested no liability from the EU. “This is a unique situation

30 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/9414
52/Information_for_healthcare_professionals.pdf
15